跳转至内容
Merck
  • Alloimmune responses and atherosclerotic disease after kidney transplantation.

Alloimmune responses and atherosclerotic disease after kidney transplantation.

Transplantation (2014-10-07)
Didier Ducloux, Cécile Courivaud, Jamal Bamoulid, Vincent Bisaccia, Caroline Roubiou, Thomas Crepin, Béatrice Gaugler, Caroline Laheurte, Jean-Michel Rebibou, Jean-Marc Chalopin, Philippe Saas
摘要

Chronic exposure to exogenous antigens causes accumulation of proinflammatory CD57(+)CD28(-) hyperactivated CD8(+) T cells that may promote atherosclerosis. We hypothesized that persistent alloimmune responses may induce immune activation and contribute to posttransplant atherosclerosis. This hypothesis was tested in a single-center cohort of 577 kidney transplant patients. Propensity score analysis was performed to address potential confounding variables by indication. Immune exhaustion was studied in subcohort of 103 patients. Five hundred seventy-seven consecutive renal transplant recipients were included. Seventy-seven atherosclerotic events (AE) (12.3%) occurred during a mean follow-up of 7 years. The cumulative incidence of AE increased with the number of human leukocyte antigen (HLA) mismatches (18%, 10%, and 5% in patients with 5-6, 3-4, and 0-2 mismatches, respectively; P=0.012). Human leukocyte antigen mismatch number (hazards ratio, 1.35; 95% confidence interval, 1.10-1.66, for each supplementary mismatch; P=0.005) was an independent risk factor for AE. In the propensity score match analysis, having received a well-matched kidney conferred a reduced risk of AE (hazards ratio, 0.22; 95% confidence interval, 0.05-0.95; P=0.044). We observed a significant correlation between HLA mismatch numbers and circulating CD57(+)CD28(-) CD8(+) T cells (R=0.31; P=0.017). These CD8(+) T cells were more frequent in patients with more HLA mismatches (P<0.0001). Overall, our results suggest that chronic allogeneic stimulation participates to accelerated atherosclerosis observed after transplantation.

材料
货号
品牌
产品描述

Sigma-Aldrich
硫唑嘌呤, ≥98%
Sigma-Aldrich
霉酚酸酯, ≥98% (HPLC)
Sigma-Aldrich
(±)-CPP, solid
USP
霉酚酸酯, United States Pharmacopeia (USP) Reference Standard
USP
硫唑嘌呤, United States Pharmacopeia (USP) Reference Standard
Supelco
霉酚酸酯, Pharmaceutical Secondary Standard; Certified Reference Material
环孢素, European Pharmacopoeia (EP) Reference Standard
Supelco
硫唑嘌呤, Pharmaceutical Secondary Standard; Certified Reference Material
硫唑嘌呤, European Pharmacopoeia (EP) Reference Standard
吗替麦考酚酯, European Pharmacopoeia (EP) Reference Standard
霉酚酸酯, European Pharmacopoeia (EP) Reference Standard